|
[1]
|
Walter, S. (2020) A Systematic Review and Meta-Analysis of the Efficacy of Intravenous Ketamine Infusion for Treat-ment Resistant Depression: January 2009-January 2019. Journal of Affective Disorders, 277, 831-841. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Elia, E., Grace, W., Cavanaugh, B.A., et al. (2019) Comprehensive Assessment of Side Effects Associated with a Single Dose of Ketamine in Treatment-Resistant Depression. Journal of Affective Disorders, 263, 568-575.
|
|
[3]
|
Fava, M., Marlene, P., Flynn, M., et al. (2018) Double-Blind, Place-bo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD). Molecular Psychiatry, 25, 1592-1603. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Kryst, J., Kawalec, P., Mikrut, A., et al. (2020) Efficacy of Single and Repeated Administration of Ketamine in Unipolar and Bipolar Depression: A Meta-Analysis of Randomized Clinical Trials. Pharmacological Reports, 72, 543-562.
|
|
[5]
|
Zimmermann, K.S., Richardson, R. and Baker, K.D. (2020) Es-ketamine as a Treatment for Paediatric Depression: Questions of Safety and Efficacy. The Lancet Psychiatry, 7, 827-829. [Google Scholar] [CrossRef]
|
|
[6]
|
Corriger, A. and Pickering, G. (2019) Ketamine and Depres-sion: A Narrative Review. Drug Design, Development and Therapy, 13, 3051-3067. [Google Scholar] [CrossRef]
|
|
[7]
|
Bartoli, F. and Wlkinson, S.T. (2019) Ketamine and Esketamine for Suicidal Ideation: Recent Progress and Practical Issues. Australian & New Zealand Journal of Psychiatry, 54, 206-207. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Domany, Y., Shelton, R.C. and McCullumsmith, C.B. (2019) Ketamine for Acute Suicidal Ideation, an Emergency Department Intervention: A Randomized, Double-Blind, Place-bo-Controlled, Proof-of-Concept Trial. [Google Scholar] [CrossRef]
|
|
[9]
|
Witt, K., Potts, J., Hubers, A., et al. (2019) Ketamine for Suicidal Idea-tion in Adults with Psychiatric Disorders: A Systematic Review and Meta-Analysis of Treatment Trials. Australian & New Zealand Journal of Psychiatry, 54, 29-45. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ren, L., Deng, J., Min, S., et al. (2018) Ketamine in Electrocon-vulsive Therapy for Depressive Disorder: A Systematic Review and Meta-Analysis. Journal of Psychiatric Research, 104, 144-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Ritter, P., Findeis, H. and Bauer, M. (2019) Ketamine in the Treatment of Depressive Episodes. Pharmacopsychiatry, 53, 45-50. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Sakurai, H., Jain, F., Foster, S., et al. (2020) Long-Term Outcome in Outpatients with Depression Treated with Acute and Maintenance Intravenous Ketamine: A Retrospective Chart Review. Journal of Affective Disorders, 276, 660-666. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Yang, C., Yang, J.J., Luo, A.L., et al. (2019) Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites. Translational Psychi-atry, 9, 280-289. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Peng, F.Z., Fan, J., Ge, T.T., et al. (2020) Rapid An-ti-Depressant-Like Effects of Ketamine and Other Candidates: Molecular and Cellular Mechanisms. Cell Proliferation, 53, e12804. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Włodarczyk, A. and Cubała, W.J. (2020) Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Sympto-matology: Literature Review and Analysis. Medicina, 56, Article No. 67. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
McIntyrea, R.S., Carvalhoa, I.P., Lui Leanna, M.W., et al. (2020) The Effect of Intravenous, Intranasal, and Oral Ketamine in Mood Disorders: A Meta-Analysis. Journal of Affective Dis-orders, 276, 576-584. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
McIntyre, R.S., Lipsits, O., Rodrigues, N.B., et al. (2022) The Ef-fectiveness of Ketamine on Anxiety, Irritability, and Agitation: Implications for Treating Mixed Feature in Adults with Major Depressive or Bipolar Disorder. Bipolar Disorders, 22, 831-840. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Abdallah, C.G., Sanacora, G., Duman, R.S., et al. (2018) The Neurobiology of Depression, Ketamine and Rapid-Acting Antidepressants: Is It Glutamate Inhibition or Activation? Pharmacology and Therapeutics, 190, 148-158. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
丁钦, 解成兰, 岳苏阳, 等. 艾司氯胺酮临床应用研究进展[J]. 实用药物与临床, 2022, 25(8): 754-758.
|
|
[20]
|
姚博炜, 郁丽娜, 刘鹤, 等. 艾司氯胺酮在临床应用中的研究进展[J]. 齐齐哈尔医学院学报, 2022, 43(6): 566-570.
|
|
[21]
|
贾涛, 腾金亮. 新型麻醉镇痛药: 艾司氯胺酮[J]. 中国临床药理学与治疗学, 2022, 27(7): 834-840.
|